World Journal of Hepatology - Baishideng Publishing Group

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 2

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5738)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-4) series.

Item

Count

PDF

403

WORD

HTML

3107

Figures (1-1)

415

Tables (1-4)

354

Sum=4369

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

466

Download

903

Sum=1369

Feb 27, 2022 (publication date) through Nov 25, 2024

Times Cited of This Article

Times Cited (6)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Cited by in CrossRef

For:	Fassio E, Barreyro FJ, Pérez MS, Dávila D, Landeira G, Gualano G, Ruffillo G. Hepatocellular carcinoma in patients with metabolic dysfunction-associated fatty liver disease: Can we stratify at-risk populations? World J Hepatol 2022; 14(2): 354-371 [PMID: 35317172 DOI: 10.4254/wjh.v14.i2.354]
URL:	https://www.wjgnet.com/1948-5182/full/v14/i2/354.htm

Number	Citing Articles
1	Masayuki Ueno, Haruhiko Takeda, Atsushi Takai, Hiroshi Seno. Risk factors and diagnostic biomarkers for nonalcoholic fatty liver disease-associated hepatocellular carcinoma: Current evidence and future perspectives. World Journal of Gastroenterology 2022; 28(27): 3410-3421 doi: 10.3748/wjg.v28.i27.3410 Abstract(1022) \| Core Tip(532) \| Full Article(HTML)(3680) \| Full Article (PDF)-606K(439) \| Full Article (Word)-133K(79) \| Audio-706K(9) \| Peer-Review Report-225K(102) \| Answering Reviewers-113K(94) \| Times Cited (12) \| Total Visits (8340) \| Open
2	Muhammad Imran Ahmad, Muhammad Umair Khan, Sudha Kodali, Akshay Shetty, S Michelle Bell, David Victor. Hepatocellular Carcinoma Due to Nonalcoholic Fatty Liver Disease: Current Concepts and Future Challenges. Journal of Hepatocellular Carcinoma 2022; : 477 doi: 10.2147/JHC.S344559
3	Carmen Colaci, Maria Luisa Gambardella, Giuseppe Guido Maria Scarlata, Luigi Boccuto, Carmela Colica, Francesco Luzza, Emidio Scarpellini, Nahum Mendez-Sanchez, Ludovico Abenavoli. Dysmetabolic comorbidities and non-alcoholic fatty liver disease: a stairway to metabolic dysfunction-associated steatotic liver disease. Hepatoma Research 2024; 10: 16 doi: 10.20517/2394-5079.2023.134
4	Cristiane Valle Tovo, Angelo Zambam de Mattos, Gabriela Perdomo Coral, Giovana D P Sartori, Livia Villela Nogueira, Gustavo Tovo Both, Cristiane A Villela-Nogueira, Angelo A de Mattos. Hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis. World Journal of Gastroenterology 2023; 29(2): 343-356 doi: 10.3748/wjg.v29.i2.343 Abstract(709) \| Core Tip(619) \| Full Article(HTML)(3562) \| Full Article (PDF)-3376K(372) \| Full Article (Word)-377K(54) \| Audio-946K(6) \| Peer-Review Report-183K(61) \| Answering Reviewers-82K(61) \| Times Cited (11) \| Total Visits (7837) \| Open
5	Takashi Saito, Mutsumi Tsuchishima, Mikihiro Tsutsumi, Joseph George. Molecular pathogenesis of metabolic dysfunction‐associated steatotic liver disease, steatohepatitis, hepatic fibrosis and liver cirrhosis. Journal of Cellular and Molecular Medicine 2024; 28(12) doi: 10.1111/jcmm.18491
6	Xia Niu, Yanan Meng, Yucheng Wang, Guiling Li. Established new compound IMB16-4 self-emulsifying drug delivery systems for increasing oral bioavailability and enhancing anti-hepatic fibrosis effect. Biomedicine & Pharmacotherapy 2022; 154: 113657 doi: 10.1016/j.biopha.2022.113657